孕期胆管癌的生存率和预测因素:化疗是否总是答案?
Sakhr Alshwayyat1,2,3, Haya Kamal4, Tala Abdulsalam Alshwayyat5
1Kern Medical (UCLA David Geffen School of Medicine Affiliate), Bakersfield, CA.
Medicine
|December 23, 2025
概括
化疗可能无法改善妊娠期胆管癌患者的生存率. 这项研究发现治疗选择之间没有显著的生存差异,并将年龄,转移和婚姻状况确定为关键预后因素.
科学领域:
- 妇科 妇科 妇科 妇科
- 在瘤学瘤学.
- 医疗信息学 医疗信息学
背景情况:
- 妊娠性胆瘤 (GC) 是一种高度恶性妊娠性热囊细胞瘤,具有早期血管入侵和转移.
- 目前的FIGO建议缺乏关于GC最佳化疗时间的共识.
- 有效的预后模型和治疗策略对于改善患者的治疗结果至关重要.
研究的目的:
- 评估化疗对妊娠期胆管癌患者的生存的影响.
- 开发和验证机器学习 (ML) 预后模型,用于预测GC的5年生存率.
- 确定影响GC生存的显著预后因素.
主要方法:
- 从SEER数据库 (2000-2020年) 分析了732名经组织学确认的GC患者.
- 预后因素的考克斯回归和治疗选择的卡普兰-梅尔分析.
- 开发和验证5ML模型 (包括随机森林分类器) 用于使用AUC-ROC分析预测生存.
主要成果:
- 在化疗,单独手术或联合手术和化疗之间没有观察到显著的生存差异.
- 老年,诊断时的转移和婚姻状况被确定为显著的负面预后因素.
- 随机森林分类模型在预测5年生存率方面表现最高,年龄,婚姻状况和转移是关键预测因素.
结论:
- 目前的证据表明,化疗可能不会为妊娠期胆管癌患者提供生存益处.
- 年龄,转移状态和婚姻状况是GC的关键预后指标.
- 进一步的多中心前性研究是有必要的,以澄清在GC管理中开始化疗的作用和最佳时间.
相关概念视频
01:21Cancer Survival Analysis
626
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
626
01:20Comparing the Survival Analysis of Two or More Groups
531
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
531
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K